LAUREN RESPESS: Open Payments
NPI 1043784648 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,177 in 63 payments from 20 companies in 2025. Trend: 2023 $1,264 · 2024 $1,137 · 2025 $1,177
Food & beverage: $1,177
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $151 |
| ABBVIE INC. | 9 | $145 |
| Amneal Pharmaceuticals LLC | 6 | $127 |
| Axsome Therapeutics, Inc. | 6 | $123 |
| TOLMAR, INC. | 4 | $88 |
| Lilly USA, LLC | 4 | $71 |
| Noven Therapeutics, LLC | 3 | $57 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
Products named: CAPLYTA, UNITHROID, Auvelity, JATENZO, QULIPTA, MOUNJARO, Xelstrym, TRELEGY ELLIPTA.
Industry payments across LA — which companies pay providers there.
